NCT01068249View on ClinicalTrials.gov

Letrozole and RAD001 With Advanced or Recurrent Endometrial Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

April 30, 2010

Primary Completion Date

April 30, 2028

Study Completion Date

April 30, 2028

Conditions
Endometrial Cancer
Interventions
DRUG

Letrozole

2.5 mg daily by mouth every day, at same time as Everolimus.

DRUG

RAD001 (Everolimus)

10 mg by mouth daily

Trial Locations (2)

77030

University of Texas MD Anderson Cancer Center, Houston

07962

Morristown Memorial Hospital, Women's Cancer Center, Morristown

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER